Affordable Access

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

Authors
  • Iversen, Peter
  • Johansson, Jan-Erik
  • Lodding, Pär
  • Lukkarinen, Olavi
  • Lundmo, Per
  • Klarskov, Peter
  • Tammela, Teuvo L J
  • Tasdemir, Ilker
  • Morris, Tom
  • Carroll, Kevin
Type
Published Article
Journal
The Journal of Urology
Publisher
Elsevier
Publication Date
Nov 01, 2004
Volume
172
Issue
5 Pt 1
Pages
1871–1876
Identifiers
PMID: 15540741
Source
Medline
License
Unknown

Abstract

Bicalutamide (150 mg) provides significant benefit in patients with locally advanced disease. In previously untreated patients there may be a tumor burden below which endocrine therapy provides no benefit or may even decrease survival.

Report this publication

Statistics

Seen <100 times